Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial
Circulation: Cardiovascular Interventions · 2025-07 · 18 (7)
DOI: 10.1161/circinterventions.124.015197 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025-07. Verfasst von Tetsuya Ishikawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Japan (T. Ishikawa). Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Coronary Artery Disease, Hemorrhage, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The effects of the aspirin-free strategy on bleeding and cardiovascular events were unknown in patients with high bleeding risk (HBR), with or without acute coronary syndrome (ACS), undergoing percutaneous coronary intervention. METHODS: We conducted a subgroup analysis stratified by ACS among patients with HBR in the STOPDAPT-3 trial (Short and Optimal Duration of Dual Antiplatelet Therapy-3), which randomly compared no-aspirin (prasugrel monotherapy) with dual antiplatelet therapy (DAPT) in patients with ACS and HBR. RESULTS: There were 3258 patients with HBR, including 1803 ACS and 1455 non-ACS patients. The effects of no-aspirin compared with DAPT at 1 month after percutaneous coronary intervention were not significant for major bleeding regardless of ACS or non-ACS (7.3% versus 7.9%; hazard ratio [HR], 0.91 [95% CI, 0.65–1.28], and 3.1% versus 2.9%; HR, 1.06 [95% CI, 0.58–1.93]; P interaction=0.66). There was a numerically higher risk in the no-aspirin group relative to the DAPT group for a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke in patients with ACS, but not in patients with non-ACS (7.9% versus 5.8%; HR, 1.39 [95% CI, 0.97–1.99], and 2.4% versus 3.0%; HR, 0.78 [95% CI, 0.41–1.47]; P interaction=0.12). There was a significant treatment-by-subgroup interaction for myocardial infarction (1.6% versus 0.3%; HR, 4.57 [95% CI, 1.31–15.89], and 1.4% versus 1.8%; HR, 0.78 [95% CI, 0.34–1.77]; P interaction=0.02). CONCLUSIONS: The aspirin-free strategy compared with the DAPT strategy failed to reduce major bleeding in patients with HBR irrespective of ACS. There was a signal of the excess risk of the aspirin-free strategy relative to the DAPT strategy for cardiovascular events, myocardial infarction in particular, in patients with ACS, but not in patients with non-ACS. The aspirin-free strategy may be considered as a potential treatment option after percutaneous coronary intervention in patients with non-ACS. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04609111.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Japan (T. Ishikawa).
- Department of Cardiovascular Medicine, Saga University, Japan (M.N.).
- Division of Cardiology, Hirakata Kohsai Hospital, Japan (H.W., H.T., T. Kimura).
- Department of Clinical Epidemiology, Hyogo College of Medicine, Japan (T.M.).
- Department of Cardiology, Kokura Memorial Hospital, Japan (K.Y., K.A.).
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (Y.O., R.N., K.O.).
ORCID-Profile: Tetsuya Ishikawa, Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Ruka Yoshida, Gaku Nakazawa, Itsuro Morishima, Hirosada Yamamoto, Koh Ono, Takeshi Kimura
Zitieren
APA
Ishikawa, T., Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Obayashi, Y., Nishikawa, R., Ando, K., Suwa, S., Isawa, T., Takenaka, H., Yoshida, R., Suzuki, H., Nakazawa, G., Kusuyama, T., Morishima, I., Hojo, S., Tsutsumi, J., Yamamoto, H., …, & Kimura, T. (2025). Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial. Circulation: Cardiovascular Interventions, 18(7). https://doi.org/10.1161/circinterventions.124.015197
Vancouver
Ishikawa T, Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, et al. Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial. Circulation: Cardiovascular Interventions. 2025;18(7). doi:10.1161/circinterventions.124.015197
BibTeX
@article{Ishikawa2025,
author = {Ishikawa, Tetsuya and Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Yamamoto, Ko and Obayashi, Yuki and Nishikawa, Ryusuke and Ando, Kenji and Suwa, Satoru and Isawa, Tsuyoshi and Takenaka, Hiroyuki and Yoshida, Ruka and Suzuki, Hiroshi and Nakazawa, Gaku and Kusuyama, Takanori and Morishima, Itsuro and Hojo, Syun and Tsutsumi, Joshi and Yamamoto, Hirosada and Ueda, Hiroshi and Ono, Koh and Kimura, Takeshi},
title = {Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial},
journal = {Circulation: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {7},
doi = {10.1161/circinterventions.124.015197}
}
EUVIMED